PAMS
WAPSU
WNPU
WeMeReC
YCC WalesNews
-
One Wales Interim Commissioning Advice During COVID-19 Pandemic
Abiraterone (ZYTIGA®), enzalutamide (Xtandi®) and apalutamide (Erleada®) for the treatment of hormone-sensitive prostate cancer during the COVID-19 pandemic. April 2020.
Events
-
National Prescribing Indicator Subgroup meeting
WAPSU held its annual AWPAG National Prescribing Indicator (NPI) Subgroup meeting to start the process of developing the NPIs for 2019–2020.
What's new
AWTTC
WAPSUAbout Us
Our work at AWTTC focuses on:
- • Health technology appraisal
- • Medicines optimisation
- • Medicines safety, including the reporting of serious adverse reactions
- • Education
- • Toxicology services
- • Prescribing analysis
We provide professional secretariat, pharmaceutical, clinical and health economics support to AWMSG and its subgroups.
We co-ordinate and support the Individual Patient Funding Request (IPFR) process following national consultation and the new One Wales Interim Commissioning Process.
We also manage the Wales Patient Access Scheme, a scheme introduced to enable manufacturers of medicines to offer a price reduction or rebate, thereby improving the cost-effectiveness of a medicine.
Organisations
-
AWTTC
Providing prescribing and medicines optimisation services
-
PAMS
Improving access to medicines
-
WAPSU
Analysing prescribing data and developing medicines optimisation resources
-
WeMeReC
Providing education in therapeutics, prescribing and behavioural change
-
WNPU
Providing national advice and local treatment for poisoned patients
-
YCC Wales
Monitoring adverse drug reactions
AWTTC
All Wales Therapeutics and Toxicology Centre
Why? Create a healthier, better informed Wales
How? By excellence in delivery of a portfolio of services in Therapeutics and Toxicology
What? Aim to be the authority on therapeutics and toxicology in Wales, liaising with, informing and assisting healthcare professionals, involving patients and the general public and advising Welsh Government, as well as engaging with the pharmaceutical industry
Patient Access to Medicine Service
Why? Improve access to medicines for patients in Wales
How? Assessment of the best available evidence using robust, transparent and inclusive processes
What? Appraise health technologies and assess the latest evidence
Welsh Analytical Prescribing Support Unit
Why? Improve health by optimising the way medicines are used in Wales
How? Use of the latest evidence and data to guide best practice and provide insight and context for prescribers
What? Analyse medicines usage data and forecast prescribing activity; develop guidelines and educational resources; facilitate the Wales Patient Access Scheme processes
Welsh Medicines Resource Centre
Why? Improve the appropriate use of medicines in NHS Wales
How? Education in therapeutics, prescribing and behavioural change for all
What? Produce a combination of digital and face-to-face learning opportunities
Welsh National Poisons Unit
Why? Improve the clinical outcome of poisoned patients
How? 24/7 bespoke telephone advice, online poison database and local treatment unit
What? Provide 24-hour emergency advice to health professionals in the UK and Ireland
Yellow Card Centre Wales
Why? Improve the safety of medicines for patients in Wales
How? Education in medicines safety, the Yellow Card scheme and side effect reporting
What? Promote the timely and appropriate reporting of suspected side effects
Organisations
AWTTC
Providing prescribing and medicines optimisation services
AWTTC
Providing prescribing and medicines optimisation services
AWTTC
All Wales Therapeutics and Toxicology Centre
Why? Create a healthier, better informed Wales
How? By excellence in delivery of a portfolio of services in Therapeutics and Toxicology
What? Aim to be the authority on therapeutics and toxicology in Wales, liaising with, informing and assisting healthcare professionals, involving patients and the general public and advising Welsh Government, as well as engaging with the pharmaceutical industry
WAPSU
Analysing prescribing data and developing medicines optimisation resources
WAPSU
Analysing prescribing data and developing medicines optimisation resources
WAPSU
Welsh Analytical Prescribing Support Unit
Why? Improve health by optimising the way medicines are used in Wales
How? Use of the latest evidence and data to guide best practice and provide insight and context for prescribers
What? Analyse medicines usage data and forecast prescribing activity; develop guidelines and educational resources; facilitate the Wales Patient Access Scheme processes
WeMeReC
Providing education in therapeutics, prescribing and behavioural change
WeMeReC
Providing education in therapeutics, prescribing and behavioural change
WeMeReC
Welsh Medicines Resource Centre
Why?Improve the appropriate use of medicines in NHS Wales
How? Education in therapeutics, prescribing and behavioural change for all
What? Produce a combination of digital and face-to-face learning opportunities
WNPU
Providing national advice and local treatment for poisoned patients
WNPU
Providing national advice and local treatment for poisoned patients
WNPU
Welsh National Poisons Unit
Why? Improve the clinical outcome of poisoned patients
How?24/7 bespoke telephone advice, online poison database and local treatment unit
What? Provide 24-hour emergency advice to health professionals in the UK and Ireland
PAMS
Improving access to medicines
PAMS
Improving access to medicines
PAMS
Patient Access to Medicines Service
Why? Improve access to medicines for patients in Wales
How? Assessment of the best available evidence using robust, transparent and inclusive processes
What? Appraise health technologies and assess the latest evidence
YCC Wales
Monitoring adverse drug reactions
YCC Wales
Monitoring adverse drug reactions
YCC Wales
Yellow Card Centre Wales
Why? Improve the safety of medicines for patients in Wales
How? Education in medicines safety, the Yellow Card scheme and side effect reporting
What? Promote the timely and appropriate reporting of suspected side effects